Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
28
UTMD Quote, Financials, Valuation and Earnings
Last price:
$55.97
Seasonality move
:
1.69%
Day range:
$55.86 - $56.50
52-week range:
$51.26 - $65.56
Dividend yield:
2.19%
P/E ratio:
15.83x
P/S ratio:
4.76x
P/B ratio:
1.52x
Volume:
10.1K
Avg. volume:
15.9K
1-year change:
-8.96%
Market cap:
$179.3M
Revenue:
$40.9M
EPS (TTM):
$3.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | -- | -- | -- | -- |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.5M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
CATX
Perspective Therapeutics, Inc.
|
$211.4K | -$0.35 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$18M | -- | 11.04% | -- | $36.00 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$16.8M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$55.96 | -- | $179.3M | 15.83x | $0.31 | 2.19% | 4.76x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$6.28 | $9.00 | $228.2M | -- | $0.00 | 0% | 52.09x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.7500 | $12.3077 | $204.4M | -- | $0.00 | 0% | 186.46x |
|
ELMD
Electromed, Inc.
|
$29.12 | $36.00 | $242.9M | 31.33x | $0.00 | 0% | 3.88x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.80 | $11.00 | $144.8M | 25.90x | $0.00 | 0% | 2.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0.2% | 1.020 | 0.12% | 29.22x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.342 | 164.57% | 0.11x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.105 | -- | 4.58x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.674 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$5.1M | $2.6M | 9.75% | 9.78% | 26.61% | $3.9M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Utah Medical Products, Inc. vs. Competitors
-
Which has Higher Returns UTMD or AIM?
AIM ImmunoTech has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -10571.43%. Utah Medical Products, Inc.'s return on equity of 9.78% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About UTMD or AIM?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Utah Medical Products, Inc., analysts believe AIM ImmunoTech is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is UTMD or AIM More Risky?
Utah Medical Products, Inc. has a beta of 0.332, which suggesting that the stock is 66.781% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock UTMD or AIM?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.19%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or AIM?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Utah Medical Products, Inc.'s net income of $2.6M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.83x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.83x $9.8M $2.6M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns UTMD or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -2301.55%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About UTMD or ARMP?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 43.31%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is UTMD or ARMP More Risky?
Utah Medical Products, Inc. has a beta of 0.332, which suggesting that the stock is 66.781% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.292, suggesting its more volatile than the S&P 500 by 29.177%.
-
Which is a Better Dividend Stock UTMD or ARMP?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.19%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or ARMP?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.83x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 52.09x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.83x $9.8M $2.6M ARMPArmata Pharmaceuticals, Inc.52.09x -- $1.2M -$26.7M
-
Which has Higher Returns UTMD or CATX?
Perspective Therapeutics, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -12425.36%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About UTMD or CATX?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 347.55%. Given that Perspective Therapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is UTMD or CATX More Risky?
Utah Medical Products, Inc. has a beta of 0.332, which suggesting that the stock is 66.781% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock UTMD or CATX?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.19%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or CATX?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Utah Medical Products, Inc.'s net income of $2.6M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.83x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 186.46x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.83x $9.8M $2.6M CATXPerspective Therapeutics, Inc.186.46x -- $209K -$26M
-
Which has Higher Returns UTMD or ELMD?
Electromed, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of 12.65%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About UTMD or ELMD?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 23.63%. Given that Electromed, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Electromed, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 ELMDElectromed, Inc.4 0 0 -
Is UTMD or ELMD More Risky?
Utah Medical Products, Inc. has a beta of 0.332, which suggesting that the stock is 66.781% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.
-
Which is a Better Dividend Stock UTMD or ELMD?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.19%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or ELMD?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Electromed, Inc.'s net income of $2.1M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.83x while Electromed, Inc.'s PE ratio is 31.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 3.88x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.83x $9.8M $2.6M ELMDElectromed, Inc.3.88x 31.33x $16.9M $2.1M
-
Which has Higher Returns UTMD or PLX?
Protalix Biotherapeutics, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of 13.19%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About UTMD or PLX?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 511.11%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is UTMD or PLX More Risky?
Utah Medical Products, Inc. has a beta of 0.332, which suggesting that the stock is 66.781% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.
-
Which is a Better Dividend Stock UTMD or PLX?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.19%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or PLX?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.83x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 2.29x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.83x $9.8M $2.6M PLXProtalix Biotherapeutics, Inc.2.29x 25.90x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
